Efficacy and Safety of Mexidol® in Stroke Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.
Also called NCT06437626
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 304 participants
- Sponsor
- Registry
-
NCT06437626
-
- Other papers using this trial's data
- [Multimodal antioxidant therapy in ischemic stroke: from MIR trial to bedside]
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Kazakhstan, Russia, Uzbekistan
- Registry status
- Completed
Technical summary
Registry record NCT06437626. Randomized; double masking; primary purpose treatment. Start 2019-11-18 (actual); primary completion 2023-08-18 (actual). Results posted on 2025-12-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Mexidol® in Stroke Therapy
- Acronym
- MIR
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Mexidol (Ethylmethylhydroxypyridine Succinate)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pharmasoft
Record details
- Record id
cardio:ct-nct06437626- Content hash
1a3b8de608a1aa214f95da6a57918dd3437c0f469d2fcbe93dae53b0b74769ab